Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Sep-Oct;2(5):460-70.
doi: 10.1038/sj.neo.7900104.

Disruption of cell cycle kinetics by benzo[a]pyrene: inverse expression patterns of BRCA-1 and p53 in MCF-7 cells arrested in S and G2

Affiliations

Disruption of cell cycle kinetics by benzo[a]pyrene: inverse expression patterns of BRCA-1 and p53 in MCF-7 cells arrested in S and G2

B D Jeffy et al. Neoplasia. 2000 Sep-Oct.

Abstract

The effects of a ligand of the aromatic hydrocarbon receptor (AhR), benzo[a] pyrene (B[ a]P), and its metabolite, BPDE (7r,8t-dihydroxy-9t,10t-epoxy-7,8,9,10-tetrahydro-benzo[a]pyrene), on BRCA-1 levels and cell cycle kinetics were determined in MCF-7 breast cancer cells. Exposure of asynchronous MCF-7 cells for 72 hours to a non-cytotoxic dose of 0.5 microM B[a]P triggered a three-fold reduction in BRCA-1 protein. In MCF-7 cells resistant (20% to 30%) to genotoxic concentrations of B[a]P (1 to 5 microM), the loss of BRCA-1 protein was coupled with pausing in S-phase and G2/M, and accumulation of p53, mdm2 and p21. Treatment of MCF-7 cells synchronized in S-phase (72%) with B[a]P prolonged the arrest in S-phase, although this checkpoint was transient since cells resumed to G2/M after 12 hours with reduced levels of BRCA-1. In these cells, levels of p53 were increased, whereas the cellular content of p21 remained unaltered. In contrast, the co-treatment with the AhR antagonist, alpha-naphthoflavone (ANF), abrogated the deleterious effects of B[a]P on BRCA-1 expression, while preventing the accumulation of p53 and disruption of cell cycle profile. These findings suggest that the AhR mediated the inverse expression patterns of BRCA-1 and p53 upon exposure to B[a]P. The treatment with BPDE induced S-phase arrest and reduced BRCA-1 mRNA levels. The negative effects of BPDE on BRCA-1 expression were not transient since removal of BPDE did not allow complete reversal of the repression. These cumulative data suggest that the B[a]P metabolite, BPDE, may play a key role in disruption of BRCA-1 expression and cell cycle kinetics in breast epithelial cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dose-response effects of B[a]P on cell viability and BRCA-1. (A) MCF-7 cells were cultured in the presence of increasing concentrations of B[a]P for 72 hours. Bars represent average cell number±SD from three independent wells counted in triplicate (n = 9). (B) Western blotting of BRCA-1 protein. Cell extracts were obtained from MCF-7 cells cultured for 72 hours in control DMEM/F12 containing 10% FCS, basal medium plus vehicle (DMSO), or increasing concentrations of B[a]P. The bands in panel B are immunocomplexes visualized by incubating Western blots with BRCA-1 (Ab-2) or β-actin (Ab-1) antibodies.
Figure 2
Figure 2
Time-dependent effects of B[a]P on BRCA-1 and cell cycle checkpoints. Asynchronous MCF-7 cells were cultured for various periods of time in basal DMEM/F12 plus 10% FCS or basal medium containing 5 µM B[a]P. At the end of the incubation periods, cell extracts were analyzed for their content in BRCA-1, p53, p21, and mdm2 protein. The control bands are β-actin immunocomplexes.
Figure 3
Figure 3
B[a]P induces S-phase and G2/M accumulation. Asynchronous MCF-7 cells were cultured for 24, 48, and 72 hours in basal DMEM/F12 plus 10% FCS, basal medium containing the vehicle (DMSO) or vehicle plus 5 µM B[a]P. Cell cycle profiles were analyzed by flow cytometry as described in Materials and Methods section. Bars represent percentages of cells in G0/G1, S, and G2/M representative of three separate experiments with standard deviations lower than 3%.
Figure 4
Figure 4
B[a]P delays escape from S-phase and extends transit through G2/M. MCF-7 cells were synchronized in S-phase with aphidicolin (1 µg/ml) for 24 hours, after which cells were released into (C and D) basal DMEM/F12 plus 10% FCS (aphidicolin/DMEM) or (E and F) basal medium plus 5 µM B[a]P (aphidicolin/B[a]P). Cells were harvested at 12 and 24 hours after release. Cell cycle distribution was examined by flow cytometry after propidium-iodide staining. Arrowheads below the DNA histograms represent channels with most events for specific phases of the cell cycle. The profiles are representative of three independent experiments.
Figure 5
Figure 5
B[a]P-dependent accumulation in G2/M coincides with loss of BRCA-1. (A) MCF-7 cells were synchronized in S-phase with aphidicolin (1 µg/ml) for 24 hours, after which cells were released into basal DMEM/F12 plus 10% FCS, or basal medium plus 5 µM B[a]P, colchicine (0.25 µM), or colchicine plus B[a]P. Cells were harvested at 12 and 24 hours after release. Cell cycle distribution was examined by flow cytometry after propidium-iodide staining. The profiles are representative of three independent experiments. (B) Western blotting of BRCA-1, p53 and p21. After synchronization in S-phase with aphidicolin (1 µg/ml) for 24 hours, cells were released into DMEM/F12 plus 10% FCS or basal medium containing 5 µM B[a]P. Cell extracts were collected at 12 and 24 hours after release. The control bands are β-actin immunocomplexes.
Figure 6
Figure 6
ANF restores normal cell cycle distribution, BRCA-1, and inhibits the accumulation p53. Asynchronous MCF-7 cells were cultured for 72 hours in basal DMEM/F12, basal medium containing vehicle (DMSO), or 5 µM B[a]P plus increasing concentrations of ANF. Bands represent immunocomplexes of BRCA-1 and p53. The control bands are β-actin immunocomplexes.
Figure 7
Figure 7
BPDE induces S-phase arrest and reduces the potential for BRCA-1 expression. (A) Flow cytometry profile of MCF-7 cells cultured for 24 hours in basal DMEM/F12 plus 10% FCS, or basal medium plus increasing concentrations of BPDE. Bars represent average percentage of cells in G0/G1, S, and G2/M from two separate experiments. (B) RT-PCR analysis of BRCA-1 mRNA from MCF-7 cells treated with nanomolar concentrations of BPDE for 24 hours. (C) MCF-7 cells were treated for 72 hours in basal medium, or pre-treated in BPDE (500 nM)-containing medium for 0.5 1, 6 and 12 hours. At the end of the pre-incubation periods, cells were washed and cultured up to 72 hours in fresh DMEM/F12 plus 10% FCS free of BPDE. In (B) and (C), changes in BRCA-1 mRNA were assessed by RT-PCR analysis of total RNA. The PCR products represent BRCA-1 (712 bp) and control ribosomal 18S RNA (488 bp) from input cDNA corresponding to 400 ng of total RNA. Experimental conditions for semi-quantitative RT-PCR analysis of BRCA-1 were those described in Material and Methods section [22]. (D) Western blot analysis of BRCA-1 and p53. MCF-7 cells were pre-treated with BPDE (500 nM) for various periods of time and then cultured up to 72 hours in basal DMEM/F12 plus 10% FCS medium. Bands represent immunocomplexes of BRCA-1, p53 and p21. The control bands are β-actin immunocomplexes.

Similar articles

Cited by

References

    1. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA-1 required for transcription-coupled repair of oxidative damage. Science. 1998;286:804–810. - PubMed
    1. Scully R, Chen J, Plug A, Xiao Y, Waver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA-1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265–275. - PubMed
    1. Zhang H, Tombline G, Weber BL. BRCA-1, BRCA-2 and DNA damage response: collision or collusion. Cell. 1998;92:433–436. - PubMed
    1. Zhong Q, Chen C-F, Li S, Chen Y, Wang C-C, Xiao J, Chen P-L, Sharp ZD, Lee W-H. Association of BRCA-1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 1999;285:747–750. - PubMed
    1. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of BRCA-1, (5–6) early embryonic lethality by p53 or p21 null mutation. Nat Genet. 1997;16:298–302. - PubMed

Publication types

MeSH terms